Head & Neck Cancers | Specialty

The head & neck cancers condition center is a comprehensive resource for clinical news and expert insights on head & neck cancers. Read more at OncLive.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

FDA Awards Orphan Drug Designation to ZEN-3694 for NUT Carcinoma

November 18th 2025

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

Post-Operative Lymphatic ctDNA Data Shows Superior Sensitivity for Detecting Residual Disease in HPV-Independent HNSCC

November 14th 2025

Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors

November 5th 2025

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

IO102-IO103 Plus Pembrolizumab Demonstrates Favorable Activity in PD-L1–High HNSCC and NSCLC

October 29th 2025

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC

October 29th 2025

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

Toripalimab Becomes First Approved Immunotherapy for Recurrent Unresectable/Metastatic NPC in Canada

October 24th 2025

Toripalimab has been approved by Health Canada both as monotherapy and in combination with cisplatin and gemcitabine for recurrent or metastatic NPC.

Buparlisib Plus Paclitaxel Fails to Yield OS Benefit in PD-1/PD-L1–Pretreated HNSCC

October 21st 2025

Buparlisib plus paclitaxel did not show an improvement in OS vs paclitaxel alone in PD-1/PD-L1–pretreated recurrent/metastatic HNSCC.

ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC

October 19th 2025

The bispecific ADC iza-bren improved ORR and led to more durable responses vs chemotherapy in heavily pretreated recurrent or metastatic NPC.

Enfortumab Vedotin Plus Pembrolizumab Shows First-Line Activity in PD-L1+ Recurrent/Metastatic HNSCC

October 19th 2025

Enfortumab vedotin plus pembrolizumab demonstrated meaningful first-line clinical activity in PD-L1–positive recurrent or metastatic HNSCC.

Ficerafusp Alfa Earns FDA Breakthrough Therapy Designation for HPV-Negative, Recurrent/Metastatic HNSCC

October 13th 2025

The FDA granted breakthrough therapy designation to ficerafusp alfa plus pembrolizumab for metastatic/recurrent head and neck squamous cell carcinoma.

JNJ-190 Plus Anti–PD-1 Immune Checkpoint Inhibitors Generate Early Antitumor Activity in HNSCC

October 3rd 2025

Early objective responses have been shown with JNJ-1900 plus immune checkpoint inhibitors for recurrent/metastatic HNSCC.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

The OncFive: Top Oncology Articles for the Week of 9/21

September 27th 2025

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

FDA Removes REMS Program for Vandetanib for Medullary Thyroid Cancer

September 25th 2025

The FDA has removed the REMS program for vandetanib for the treatment of patients with medullary thyroid cancer.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications

September 19th 2025

The EMA’s CHMP has recommended the approval of subcutaneous pembrolizumab across all indications and perioperative pembrolizumab in locally advanced HNSCC.

FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC

September 16th 2025

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

FDA Provides Guidance on Registrational Path for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma

September 9th 2025

The FDA has provided guidance on the design of a potential phase 3 trial evaluating the ADC ozuriftamab vedotin in OPSCC.